OSMT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Jan 2022 @ 00:00):

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary...

Stats
Today's Volume	296 322
Average Volume	594 359
Market Cap	110.18M
EPS	$-0.280 ( 2021-11-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.694
ATR14	$0.0990 (8.92%)

Insider Trading

Date	Person	Action	Amount	type
2021-01-24	Klein Christopher	Sell	9 605	Ordinary Shares
2020-05-20	Cowan Gregory L	Buy	38 716	Ordinary Shares
2020-05-21	Cowan Gregory L	Sell	11 112	Ordinary Shares
2020-01-28	Schaub James	Sell	9 197	Ordinary Shares
2019-01-24	Weiss Fred G	Buy	34 403	Ordinary Shares

INSIDER POWER
0.00
Last 6 transactions
Buy: 177 968 \| Sell: 29 914

Volume Correlation

Long: -0.10 (neutral)

Short: 0.02 (neutral)

Signal:(45.447) Neutral

Osmotica Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Osmotica Pharmaceuticals Correlation - Currency/Commodity

0.38
( neutral )

0.78
( moderate )

-0.69
( moderate negative )

0.43
( neutral )

-0.36
( neutral )

-0.68
( moderate negative )

Osmotica Pharmaceuticals Financials

Annual	2022
Revenue:	$49.72M
Gross Profit:	$40.27M (80.98 %)
EPS:	$-0.580

Q2	2023
Revenue:	$8.26M
Gross Profit:	$6.31M (76.43 %)
EPS:	$-0.240

Q1	2023
Revenue:	$8.83M
Gross Profit:	$6.53M (73.97 %)
EPS:	$-0.120

Q4	2022
Revenue:	$9.81M
Gross Profit:	$7.25M (73.90 %)
EPS:	$-0.180

Financial Reports:

No articles found.

Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.